Urogen Pharma (NASDAQ:URGN) Insider Sells $16,644.81 in Stock

Urogen Pharma (NASDAQ:URGN) insider Mark Schoenberg sold 871 shares of the company’s stock in a transaction dated Monday, September 8th. The shares were sold at an average price of $19.11, for a total transaction of $16,644.81. Following the transaction, the insider owned 149,025 shares in the company, valued at $2,847,867.75. This represents a 0.58% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Mark Schoenberg also recently made the following trade(s):

• On Monday, August 11th, Mark Schoenberg sold 10,000 shares of Urogen Pharma stock. The stock was sold at an average price of $17.69, for a total transaction of $176,900.00.
• On Monday, July 28th, Mark Schoenberg sold 5,149 shares of Urogen Pharma stock. The shares were sold at an average price of $19.14, for a total transaction of $98,551.86.

Urogen Pharma Stock Up 0.7%

Shares of Urogen Pharma stock opened at $19.25 on Friday. The company has a market cap of $890.51 million, a price-to-earnings ratio of -5.80 and a beta of 1.10. The company’s 50 day moving average is $18.09 and its 200 day moving average is $12.79. Urogen Pharma has a twelve month low of $3.42 and a twelve month high of $21.71.

Urogen Pharma (NASDAQ:URGN) last posted its earnings results on Thursday, August 7th. The company reported ($1.05) EPS for the quarter, missing analysts’ consensus estimates of ($0.82) by ($0.23). The company had revenue of $24.22 million during the quarter, compared to the consensus estimate of $23.06 million. Urogen Pharma had a negative return on equity of 97,487.15% and a negative net margin of 164.44%. Sell-side analysts expect that Urogen Pharma will post -3.12 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several analysts recently commented on the company. Oppenheimer set a $31.00 price objective on Urogen Pharma and gave the stock a “buy” rating in a report on Friday, June 13th. Piper Sandler began coverage on Urogen Pharma in a research note on Monday, August 18th. They set an “overweight” rating and a $36.00 price target for the company. HC Wainwright reduced their price target on shares of Urogen Pharma from $50.00 to $40.00 and set a “buy” rating for the company in a research report on Monday, August 11th. The Goldman Sachs Group set a $16.00 price objective on shares of Urogen Pharma and gave the stock a “neutral” rating in a research note on Friday, June 13th. Finally, Guggenheim reissued a “buy” rating and issued a $30.00 price objective (up previously from $15.00) on shares of Urogen Pharma in a report on Friday, June 13th. One research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has assigned a Hold rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Buy” and an average price target of $32.00.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the stock. RA Capital Management L.P. purchased a new position in shares of Urogen Pharma during the 1st quarter valued at about $35,461,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its stake in Urogen Pharma by 216.6% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 4,360,524 shares of the company’s stock worth $48,227,000 after acquiring an additional 2,983,368 shares during the period. Soleus Capital Management L.P. purchased a new position in Urogen Pharma during the second quarter valued at approximately $29,934,000. Toronto Dominion Bank bought a new position in shares of Urogen Pharma in the fourth quarter worth approximately $18,628,000. Finally, Vestal Point Capital LP boosted its position in shares of Urogen Pharma by 307.5% in the fourth quarter. Vestal Point Capital LP now owns 1,630,000 shares of the company’s stock worth $17,360,000 after purchasing an additional 1,230,000 shares during the period. Institutional investors own 91.29% of the company’s stock.

Urogen Pharma Company Profile

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.